CORRECTION Open Access



Correction to: Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis

Huihui Jiang^{1†}, Aiqun Xu^{2†}, Wanli Xia^{3†}, Xingyuan Xia¹, Pulin Li¹, Binbin Zhang¹, Ke Zhu¹, Sijing Zhou^{4,5*} and Ran Wang^{1*}

Correction to: Cancer Cell Int (2021) 21:426

https://doi.org/10.1186/s12935-021-02100-w

Following the publication of the original article [1], we were notified that the affiliation of the third author was incorrect.

- Originally published affiliation: Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China
- Corrected affiliation: Department of Thoracic Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China

The original article has been corrected.

Author details

¹Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China. ²Department of General Medicine, Hefei Second People's Hospital, Hefei 230001, China. ³Department of Thoracic Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China. ⁴Hefei Third Clinical College of Anhui Medical University, Hefei 230022, China. ⁵Hefei Prevention and Treatment Center for Occupational Diseases, Hefei 230022, China.

Published online: 04 October 2021

Reference

 Jiang H, Xu A, Xia W, Xia X, Li P, Zhang B, Zhu K, Zhou S, Wang R. Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis. Cancer Cell Int. 2021;21:426. https://doi.org/10.1186/s12935-021-02100-w.

The original article can be found online at https://doi.org/10.1186/s12935-021-02100-w.

Full list of author information is available at the end of the article



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/loublicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data

^{*}Correspondence: zhousijing@yeah.net; wangran@ahmu.edu.cn

[†]Huihui Jiang, Aiqun Xu and Wanli Xia contributed equally to this work

¹ Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China

⁴ Hefei Third Clinical College of Anhui Medical University, Hefei 230022,

Jiang *et al. Cancer Cell Int* (2021) 21:520 Page 2 of 2

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in

published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- $\bullet\,$ thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

